1. Long-term outcomes of imatinib treatment for chronic myeloid leukemia.;Hochhaus;N Engl J Med,2017
2. IMS Institute for Healthcare Informatics. Medicines Use and Spending in the US. May 4, 2017. https://www.iqvia.com/institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2016. Accessed May 14, 2017.
3. IMS Institute for Healthcare Informatics. Global Oncology Trend Report. June 2016. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trend-report-2016.pdf. Accessed April 10, 2018.
4. US Department of Health and Human Services. High-Price Drugs are Increasing Federal Payments for Medicare Part D Catastrophic Coverage. January 2017. https://oig.hhs.gov/oei/reports/oei-02-16-00270.pdf. Accessed September 24, 2017.
5. US Food and Drug Administration. FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. July 17, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm. Accessed September 24, 2017.